Lundbeck enters production deal with Biovitrum for therapeutic protein  

Swedish biotech company Biovitrum has entered an agreement with Lundbeck regarding the production of a therapeutic protein

H. Lundbeck A/S has acquired the rights to produce a new therapeutic protein from the US biotech company Maxygen and has just entered a contract with the Swedish biotech company Biovitrum concerning process implementation and the production of material for further research. The agreement runs for a two and a half year period. According to Biovitrum the agreement supports their claim that the company's competencies and capacity are much sought after in the therapeutic proteins field.


Formerly a division of the pharmaceutical company Pharmacia, Biovitrum researches into metabolic diseases, and is active in the development, production and marketing of recombinant and plasma derived protein drugs. Biovitrum is one of the largest biotech companies in Europe with close to 900 employees. H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. The company has approx. 4,800 employees. Maxygen, established in 1997, has emerged as a leader in the evolution and optimization of genes and proteins for the creation of improved human therapeutics products. The company is headquartered in California but has also established an office in Denmark, just north of Copenhagen.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×